Results 11 to 20 of about 176,716 (160)
Acta Pharmaceutica Sinica B, 2023 Since the utilization of anthracyclines in cancer therapy, severe cardiotoxicity has become a major obstacle. The major challenge in treating cancer patients with anthracyclines is minimizing cardiotoxicity without compromising antitumor efficacy. Herein,
Kezheng Peng +10 more
doaj +1 more source
BMC Cancer, 2018 Background Olaratumab is a platelet-derived growth factor receptor-α (PDGFRα)-targeting monoclonal antibody blocking PDGFRα signaling. PDGFRα expression is associated with a more aggressive phenotype and poor ovarian cancer outcomes.
William P. McGuire +6 more
doaj +1 more source
Cells, 2018 This study aimed to examine the effect of lipid emulsion on the cardiotoxicity induced by doxorubicin in H9c2 rat cardiomyoblasts and elucidates the associated cellular mechanism.
Raghavendra Baregundi Subbarao +6 more
doaj +1 more source
PEGylated Liposomal Doxorubicin Rechallenge following Doxorubicin-induced Pancreatitis
Current Problems in Cancer: Case Reports, 2020 Drug induced pancreatitis is rare and establishing the exact causal relationship is challenging. Here, we discuss the management of a 60 year-old female patient with stage 3a breast cancer who developed doxorubicin induced pancreatitis 3 days after her ...
Luke Ardolino, Eugene Moylan
doaj +1 more source
Exosomal Doxorubicin Reduces the Cardiac Toxicity of Doxorubicin
Nanomedicine, 2015 To test the efficacy and toxicity of exosomal doxorubicin (exoDOX) compared with free doxorubicin.The cytotoxic effects of exoDOX were tested in vitro and in nude mice by measuring the tumor volume. The toxic effects were evaluated by measuring the bodyweight and through histopathologic analyses.
TOFFOLI, GIUSEPPE +8 more
openaire +3 more sources
Doxorubicin Cardiomyopathy [PDF]
Cardiology, 2009 Established doxorubicin cardiomyopathy is a lethal disease. When congestive heart failure develops, mortality is approximately 50%. Extensive research has been done to understand the mechanism and pathophysiology of doxorubicin cardiomyopathy, and considerable knowledge and experience has been gained.
Kanu, Chatterjee +3 more
openaire +2 more sources
Cardio-Oncology, 2020 Background Continuous infusion of doxorubicin or dexrazoxane pre-treatment prior to bolus doxorubicin are proven strategies to protect against doxorubicin-induced cardiotoxicity.
Jieli Li +7 more
doaj +1 more source
Tripeptide tyroserleutide plus doxorubicin: therapeutic synergy and side effect attenuation
BMC Cancer, 2008 Background Tripeptide tyroserleutide (YSL) is a novel small molecule anti-tumor polypeptide that has been shown to inhibit the growth of human liver cancer cells.
Zhou Chun-lei +9 more
doaj +1 more source
Identification of CREB3L1 as a Biomarker Predicting Doxorubicin Treatment Outcome. [PDF]
PLoS ONE, 2015 Doxorubicin has been shown to inhibit proliferation of cancer cells through proteolytic activation of CREB3L1 (cAMP response element binding protein 3-like 1), a transcription factor synthesized as a membrane-bound precursor.
Bray Denard +7 more
doaj +1 more source
Exposure to Doxorubicin Modulates the Cardiac Response to Isoproterenol in Male and Female Mice
Pharmaceuticals, 2023 Sex is a salient risk factor in the development of doxorubicin-induced cardiotoxicity. Sex differences in the heart’s ability to respond to hypertrophic stimuli in doxorubicin-exposed animals have not been reported.
Kevin Agostinucci +4 more
doaj +1 more source